Up and running again

A Boston Scientific therapy helped Esther overcome cancer pain.

Read her story

Featured stories
May 1, 2026
What is colorectal cancer, and how is it treated?

Learn the symptoms of colorectal cancer and how it is treated, including options for colorectal cancer liver metastases.

Apr 22, 2026
Interested in our Q1 2026 earnings?

Get some key highlights of our performance this quarter.

Mar 19, 2026
Four things to know about our acquisition of Nalu Medical

Learn how Boston Scientific’s acquisition of Nalu Medical expands treatment options for chronic peripheral nerve pain.

Read more stories

Press releases
May 4, 2026
Boston Scientific announces participation in Bernstein's 42nd Annual Strategic Decisions Conference and conference call discussing second quarter 2026 results

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Mike Mahoney, chairman and chief executive officer,...

Apr 26, 2026
Data at Heart Rhythm 2026 highlight key Boston Scientific therapies

Positive data for FARAPULSE™ Pulsed Field Ablation and WATCHMAN™ LAAC Devices underscore therapy safety and effectiveness in late-breaking clinical trial sessions MARLBOROUGH, Mass. and...

Apr 22, 2026
Boston Scientific announces results for first quarter 2026

Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and...

Read more press releases

In the news
Mar 29, 2026
Data supports Boston Scientific Watchman FLX™ in stroke reduction
MassDevice
The CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line option for stroke risk reduction met all primary and secondary endpoints and demonstrated superior bleeding risk reduction and similar efficacy of the WATCHMAN FLX device compared to oral anticoagulants in a broad population of patients with non-valvular atrial fibrillation.
Mar 28, 2026
HI-PEITHO kicks off ‘golden era’ in pulmonary embolism
MedPage Today
Learn how findings from the HI-PEITHO trial highlight a major advance in the treatment of immediate-risk pulmonary embolism, with ultrasound-assisted, catheter-directed thrombolysis using the EKOS™ Endovascular System reducing early complications without increasing major bleeding.
Jan 26, 2026
Hospitals are embracing pulsed field ablation. Here’s why
Modern Healthcare
Driven by an improved safety profile, strong patient demand and more predictable procedures, health systems are increasing investment in pulsed field ablation (PFA)—including technology like the FARAPULSE™ PFA Platform—to treat atrial fibrillation.
Jan 15, 2026
Lab profile: Boston Scientific’s Arbor Lakes campus was built to be reconfigurable
R&D World
Read how Boston Scientific designed its latest employee campus with an intentional focus on collaboration for rapid innovation in this interview with Stephanie Board, group vice president, Research & Development, Interventional Cardiology & Vascular Therapies.

Read more news

2024 Performance Report

When science, humanity and purpose connect, lives can be transformed

View the Report

News alerts

Sign up to receive our press releases via email

Media contacts

Business and enterprise contacts for journalists

Media resources

Imagery and other resources

Top